Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Study Says Low Disease-Activity State Can Reduce Lupus Organ Damage

Bryn Nelson, PhD  |  Issue: October 2018  |  

“We are stuck with steroids in lupus; they work and they work fast,” Dr. Petri says. “We just cannot maintain them long term at 6 mg or more.”

Other research by her group suggested that durable remission is rare among SLE patients, supporting her study’s position that LLDAS is a more reachable goal for a treat-to-target strategy.2 She agrees with Dr. Morand and Dr. van Vollenhoven that a clinical trial will be needed to confirm whether such an approach is in SLE patients’ best interests. “But now, at least, we have the target,” Dr. Morand says.

ADVERTISEMENT
SCROLL TO CONTINUE

Bryn Nelson, PhD, is a medical journalist based in Seattle.

References

  1. Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol. 2018 May 27. [Epub ahead of print]
  2. Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2017;76:547–553.

Related Articles

    Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus

    ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…

    nukeaf / shutterstock.com

    The History of Treating Lupus with Hydroxychloroquine

    Given how unexpectedly front and center hydroxychloroquine has been in discussions about the treatment of COVID-19 this year, it makes sense to look at how it became so central to the treatment of a rheumatologic condition. In 1991, an article appeared in The New England Journal of Medicine that would alter the way rheumatologists approached…

    Dr. Michelle Petri: A Guiding Light for Patients with Lupus

    Systemic lupus erythematosus (SLE) affects a substantial number of patients worldwide, with an estimated prevalence in North America of 241 per 100,000 people.1 The morbidity and mortality associated with the condition can be significant, and thus research on this disease continues to be of utmost importance. The story of one of the world’s leading experts…